ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE GHENT, Belgium, 28 May 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces it will present at the Annual Jefferies 2015 Global Healthcare Conference in New York City on Thursday, 4 June 2015 at 09:30 a.m. EST (03:30 p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of Ablynx. The presentation will provide an update on the Company's proprietary key clinical assets, its partnered programmes and the outlook for the near term future.

The presentation will be webcast live and can be accessed on the day via this link. A replay of

the webcast will be available on the Company's website, under the news & eventssection, for

90 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmesin development in various therapeutic areas including inflammation, haematology, immuno- oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact: Ablynx:

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07 m: +32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch

Associate Director Investor Relations t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com

@AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville t: +44 203 709 5700

e: ablynx@consilium-comms.com

Forward looking statement

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward -looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

distributed by